SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Bristol-Myers Squibb Company Release: ELIQUIS® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients With Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding